1 completed, 1 withdrawn. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Hitendra Patel: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer Gemcitabine, Nivolumab 10 MG/ML Intravenous Solution [OPDIVO], Cabiralizumab - Pancreatic Cancer Stage IV | Phase 2 | Completed | Hitendra Patel | 2 | 2019-10-31 | 2025-08-06 |
| High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer Ascorbic Acid, Paclitaxel protein-bound, Cisplatin - Metastatic Pancreatic Cancer, Pancreatic Cancer | Phase 1 / Phase 2 | Withdrawn | Hitendra Patel | 2019-06-01 | 2019-06-11 |
Neoplasms (2) · Pancreatic Neoplasms (2)
Gemcitabine (2) · Ascorbic Acid (1) · Cisplatin (1) · Nivolumab (1) · Taxes (1) · cabiralizumab (1)
United States (2)
Andrew Lowy, MD (1)